Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798120 · ClinicalTrials.gov registry record · Phase 3
P3 Long Term Safety Study of Once Daily SB204 in Acne
A Phase 3 study of Acne Vulgaris, sponsored by Novan.
- Completed
- Registry status
- Phase 3
- Development phase
- 601
- Enrollment target
- 20
- Study locations
NCT02798120 is a Phase 3 study of Acne Vulgaris that has completed, run by Novan. The registered enrollment target is 601 participants, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (126% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT02798120, a Phase 3 study of Acne Vulgaris, has completed, sponsored by Novan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 601 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
Conditions Studied
Interventions
- DRUG SB204 4%
Study Locations (20)
California
- CIL #146 - Anaheim
- CIL #139 - Cerritos
- CIL #216 - Chula Vista
- CIL #186 - Fresno
- CIL #210 - Fresno
- CIL #174 - Huntington Beach
- CIL #213 - La Mesa
- CIL #209 - Oceanside
- CIL #190 - Sacramento
- CIL #161 - San Diego
- CIL #113 - San Diego
- CIL #195 - Santa Ana
- CIL #119 - Santa Monica
- CIL #199 - Santa Rosa
Florida
- CIL #103 - Boca Raton
- CIL #208 - Hialeah
- CIL #212 - Homestead
Alabama
- CIL #138 - Birmingham
- CIL #218 - Mobile
Arizona
- CIL #189 - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2016-05-12 |
| Est. Completion | 2017-04-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798120
The ClinicalTrials.gov registry entry for NCT02798120 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 266-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (126% higher). The listed sponsor is Novan, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which SB204 4% is the first listed.
NCT02798120 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT02798120 about?
NCT02798120 is a clinical study titled "P3 Long Term Safety Study of Once Daily SB204 in Acne". This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
What is the current status of trial NCT02798120?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 601 participants. The study started on 2016-05-12. Estimated completion is 2017-04-27.
What conditions does trial NCT02798120 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT02798120?
The interventions under investigation include: SB204 4% (DRUG).
Who is sponsoring clinical trial NCT02798120?
This trial is sponsored by Novan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798120 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne
COMPLETED · Phase 3
-
A Study of S6G5T3 in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne
COMPLETED · Phase 3
-
Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris
COMPLETED · Phase 3
-
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
-
A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.